TOCscan
Ready-to-use Radiopharmaceutical Solution for Diagnosis & Staging of Neuroendocrine Tumors (NETs)
TOCScan® 20 MBq/mL1 and Sogacin®2 20 MBq/mL Solution for Injection
Active substance: Gallium (68Ga) edotreotide
Marketing authorization in Austria and France under the brand name Sogacin® / Marktzulassung in Österreich unter dem Markennamen Sogacin®
1. TOCscan® is approved for marketing authorization in Germany only.
2. Sogacin® is approved for marketing authorization in Austria and France only.
Patient Information / Patienteninformation:
Package Leaflet Gebrauchsinformation DE Gebrauchsinformation AT